Cargando…

Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy

Detalles Bibliográficos
Autores principales:	Ammirati, Enrico, Travi, Giovanna, Orcese, Carloandrea, Sacco, Alice, Auricchio, Sara, Frigerio, Maria, Puoti, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367013/ https://www.ncbi.nlm.nih.gov/pubmed/32754630 http://dx.doi.org/10.1016/j.ijcha.2020.100596

Ejemplares similares

Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients
por: Merli, Marco, et al.
Publicado: (2021)

Top topics in HCV research arena
por: Puoti, Massimo, et al.
Publicado: (2012)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Does interval time between liver transplant and COVID-19 infection make the difference?
por: Buscemi, Vincenzo, et al.
Publicado: (2021)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

“Efficacy of tocilizumab in treatment of COVID-19 pneumonia: A case–control study from a tertiary care hospital”
por: Barthwal, M. S., et al.
Publicado: (2023)

Hyperglycemia in Severe Falciparum Malaria: A Case Report
por: Chianura, Leonardo, et al.
Publicado: (2012)

Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection
por: Ammirati, Enrico, et al.
Publicado: (2021)

Tocilizumab in COVID-19: finding the optimal route and dose
por: Jain, Siddharth, et al.
Publicado: (2020)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Yang, Chengliang, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Neumann, Avidan U, et al.
Publicado: (2021)

Immunosuppression in HIV-Positive Heart Transplant Recipients During the Post–COVID-19 Era
por: Mahrokhian, Shant H., et al.
Publicado: (2022)

Successful treatment of a critical COVID-19 patient with tocilizumab
por: Tsao, Shih-Ming, et al.
Publicado: (2021)

WHO prequalified tocilizumab and vaccine boosters against COVID-19
por: Rahimi, Farid, et al.
Publicado: (2022)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma
por: Eberst, Lauriane, et al.
Publicado: (2020)

First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19
por: Mastroianni, Fiore
Publicado: (2020)

Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis
por: Rossotti, Roberto, et al.
Publicado: (2020)

Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021)

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19
por: Chuang, Tzu-Yi, et al.
Publicado: (2021)

Necrotizing fasciitis with slow progression in a patient with rheumatoid arthritis receiving tocilizumab
por: Goto, Kazuya, et al.
Publicado: (2022)

Abstract 42: Trends of Maintenance Immunosuppression in Hand and Facial Transplantation
por: Manjunath, Amit K., et al.
Publicado: (2018)

Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
por: Leclercq, Mathilde, et al.
Publicado: (2023)

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
por: Hassan, Mona Ali, et al.
Publicado: (2023)

Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
por: Masuccio, Fabio Giuseppe, et al.
Publicado: (2020)

Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression
por: Zuckermann, Andreas, et al.
Publicado: (2015)

A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?
por: Sereno, María, et al.
Publicado: (2020)

Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
por: Liu, Limin, et al.
Publicado: (2022)

Comment on: Conventional immunosuppression: the search for scientific evidence
por: Gandhi, Jagdeep Singh
Publicado: (2020)

The association between immunosuppressant and the outcome of COVID-19
por: Hsu, Chi-Kuei, et al.
Publicado: (2022)

Systemic leak capillary syndrome with myocardial involvement and cardiogenic shock: a case report
por: Garatti, Laura, et al.
Publicado: (2022)

Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality
por: Alteri, Claudia, et al.
Publicado: (2020)

The Maintenance of Voluntary Hospitals
por: James, H. G.
Publicado: (1923)

Favorable Outcome of COVID-19 Pneumonia in a Kidney Transplant Recipient Treated with Tocilizumab
por: Guella, Adnane, et al.
Publicado: (2020)

Fulminant myocarditis: Characteristics, treatment, and outcomes
por: Veronese, Giacomo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sr7or4u6pverlhj7mm6fksg8tt